Skip to main content
SpringerLink
Log in

Inhibition of Terfenadine Metabolism

Pharmacokinetic and Pharmacodynamic Consequences

  • Leading Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies [editorial]. JAMA 1993; 269: 1550–2

    Article  PubMed  CAS  Google Scholar 

  2. Davies AJ, Harindra V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose [letter]. BMJ 1989; 298: 325

    Article  PubMed  CAS  Google Scholar 

  3. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90

    Article  PubMed  CAS  Google Scholar 

  4. MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine [letter]. BMJ 1991; 302: 1469

    Article  PubMed  CAS  Google Scholar 

  5. Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13: 1002–3

    PubMed  CAS  Google Scholar 

  6. Mathews DR, McNutt B, Okerholm R, et al. Torsades de pointes occurring in association with terfenadine use [letter]. JAMA 1991; 266: 2375–6

    Article  PubMed  CAS  Google Scholar 

  7. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6

    Article  PubMed  CAS  Google Scholar 

  8. Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole [abstract]. Clin Pharmacol Ther 1991; 49: 130

    Google Scholar 

  9. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8

    Article  PubMed  CAS  Google Scholar 

  10. Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45: 191–3

    Article  PubMed  CAS  Google Scholar 

  11. Crane JK, Shih H-T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993; 95: 445–6

    Article  PubMed  CAS  Google Scholar 

  12. Honig PK, Wortham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53: 630–6

    Article  PubMed  CAS  Google Scholar 

  13. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014–8

    Article  PubMed  CAS  Google Scholar 

  14. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231–8

    Article  PubMed  CAS  Google Scholar 

  15. Honig P, Wortham D, Zamani K, et al. Effect of erythromycin, clarithromycin and azithromycin on the pharmacokinetics of terfenadine [abstract]. Clin Pharmacol Ther 1993; 53: 161

    Article  Google Scholar 

  16. Cantilena L, Wortham D, Zamani K, et al. Effect of cimetidine and ranitidine on the pharmacokinetics and ECG pharmacodynamics of terfenadine [abstract]. Clin Pharmacol Ther 1993; 53: 161

    Google Scholar 

  17. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989; 28: 166–70

    Article  PubMed  CAS  Google Scholar 

  18. Seyffer R, Eichelbaum M, Jensen JC, et al. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol 1989; 37: 231–3

    Article  PubMed  CAS  Google Scholar 

  19. Back DJ, Tjia JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatol 1992; 126 Suppl. 39: 14–8

    Article  PubMed  Google Scholar 

  20. Yun C, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21: 403–9

    PubMed  CAS  Google Scholar 

  21. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346–52

    Article  PubMed  CAS  Google Scholar 

  22. Algra A, Tijssen JGP, Roelandt JRTC, et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83: 1888–94

    Article  PubMed  CAS  Google Scholar 

  23. Kemp JP. Decreased antihistamine metabolism [letter]. Ann Allergy 1992; 69: 533

    PubMed  CAS  Google Scholar 

  24. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82

    Article  PubMed  CAS  Google Scholar 

  25. Henahan S. Implications of terfenadine’s interactions. Reactions 1993; 449: 3–4

    Article  Google Scholar 

  26. Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990; 11: 2275–9

    Article  PubMed  CAS  Google Scholar 

  27. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268–9

    Article  PubMed  CAS  Google Scholar 

  28. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26: 91–8

    Article  PubMed  CAS  Google Scholar 

  29. Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221–5

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstr. 112, D-70376, Stuttgart, Germany

    Kari T. Kivistö & Ulrich Klotz

  2. Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland

    Pertti J. Neuvonen

Authors
  1. Kari T. Kivistö
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pertti J. Neuvonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kivistö, K.T., Neuvonen, P.J. & Klotz, U. Inhibition of Terfenadine Metabolism. Clin. Pharmacokinet. 27, 1–5 (1994). https://doi.org/10.2165/00003088-199427010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199427010-00001

Search

Navigation